Vaccinex (VCNX)
(Delayed Data from NSDQ)
$5.38 USD
+0.25 (4.87%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $5.22 -0.16 (-2.97%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VCNX 5.38 +0.25(4.87%)
Will VCNX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VCNX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for VCNX
VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024
Vaccinex says Alzheimer's candidate buoyed by additional early-stage data
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer?s Disease and Plans to Pursue a Development Partnership
Vaccinex Provides Update on Alzheimer’s Treatment Trial
Vaccinex provide update on findings for SIGNAL-AD Phase 1b/2 trial of pepinemab